H101 + camrelizumab

H101 + camrelizumab is a combination therapy consisting of an oncolytic adenovirus (H101) and a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), known as camrelizumab. H101 is an E1B55KD-deleted recombinant human type 5 adenovirus that selectively replicates in and lyses tumor cells, also modulating the tumor microenvironment by downregulating CD47 expression to promote macrophage-mediated phagocytosis of cancer cells and increasing cytokine production (TNF, IL-12, IFN-γ). Camrelizumab blocks PD-1 on T lymphocytes, B cells, and NK cells to prevent its interaction with PD-L1/PD-L2 ligands expressed by tumor or antigen-presenting cells. This blockade restores immune function through activation of cytotoxic T lymphocytes against tumors. The combination has demonstrated synergistic anti-tumor effects in preclinical models by enhancing both innate and adaptive anti-tumor immunity[2][5][6]. It is being investigated primarily for solid tumors including glioblastoma and bladder cancer.